chevron-down Created with Sketch Beta.


Sanofi / Maze: An A-maze-ing Expansion of the Nascent Competition Doctrine?

Megan Browdie, Deborah Feinstein, Ryan Foley, and Stephen Alrick Mohr

Sanofi recently abandoned its proposal to license Maze's developmental drug to treat Pompe disease in the face of the FTC's decision to seek a preliminary injunction to block the deal. This move highlights the agency's commitment to closely scrutinizing nascent competition in life science and pharma deals. The panel will discuss the implications of the FTC's challenge.